Ubiquitin Enzyme Inhibitors Pipeline Sector to See Huge Success, States Roots Analysis in Its Report Published at MarketPublishers.com

12 Dec 2016 • by Natalie Aster

LONDON – To date, more than 45 molecules targeting ubiquitin enzymes are in clinical and/or preclinical development stages. 71% of the molecules in pipeline are targeting oncology indications. Within the oncology domain, hematologic malignancies, like relapsed/refractory multiple myeloma (MM) and acute myeloid leukemia (AML), are the key focus areas. Other indications like Parkinson’s disease, Alzheimer’s disease, Angelman syndrome and Friedreich's ataxia are also gaining developers’ interest.

A range of strategic investors and venture companies have vigorously backed the potential offered by the market. There have been 70 funding cases during the last several years, with the overall amount invested standing around USD 1.2 billion.

There are nearly 20 research/technology platforms that are presently available to give a boost to the development of ubiquitin enzyme inhibitors. Among such platforms one can mention PROTAC Technology Platform, DUBprofiler™, UbiPro™, etc.

The market is anticipated to see incredible success in the long run. Following the launch of the first wave of products, the sector is poised to register an annualized growth rate of 75% through to 2030.

In-demand research report “Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030” created by Roots Analysis gives an detailed understanding of today’s ubiquitin enzyme inhibitors pipeline landscape and also speculates on what potential this market has in the long term. It gives an extensive description of ubiquitin enzyme inhibitors in tandem with drug classes closely related to them. The study examines the current state of the market pertaining to the leading players, stage of development of pipeline products, target enzyme classes and the major indications. It provides extensive profiles limelighting clinical research details, essential preclinical/clinical findings and future market opportunity for ubiquitin enzyme inhibitors in various clinical stages. The report sheds light on different investments and grants obtained by companies involved in this domain to boost and support their research activities. The publication takes an up-close look at the partnerships that have occurred worldwide in the recent years.

More in-demand research studies by Roots Analysis are available at its page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com